RedHill Biopharma (RDHL) announced that the New York Supreme Court has awarded RedHill approximately $1.82M in legal costs and expenses in its action against Kukbo. The award follows, and is in addition to, the New York Supreme Court’s prior summary judgement award of approximately $8.25M in favor of RedHill. 9% ongoing statutory interest accrual is applicable to both the original summary judgment and the award of legal costs and expenses. RedHill also succeeded in its application to Korea’s Incheon District Court for an attachment grant against Kukbo. This provides a court-ordered seizure of Kukbo’s assets, preventing their disposal prior to judgment enforcement.
Claim 50% Off TipRanks Premium and Invest with Confidence
- Unlock hedge-fund level data and powerful investing tools designed to help you make smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis so your portfolio is always positioned for maximum potential
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on RDHL:
- RedHill Biopharma Secures $1.1 Million from Talicia’s First International Sales
- RedHill Biopharma receives Talicia licensing payments totaling $1.1M
- RedHill Biopharma Granted Nasdaq Compliance Extension
- RedHill Biopharma Gains FDA Support for Innovative Crohn’s Disease Therapy
- RedHill Biopharma receives positive FDA feedback for RHB-204 in Crohn’s Disease